Certara, Inc. (CERT)
NASDAQ: CERT · Real-Time Price · USD
10.48
+0.15 (1.45%)
Oct 26, 2026, 12:32 PM EDT - Market open
Certara Revenue
Certara had revenue of $93.27M in the quarter ending June 30, 2026, with 0.99% growth. This brings the company's total for the last twelve months to $408.45M, up 3.79% year-over-year. In the year 2025, Certara had annual revenue of $418.84M with 8.75% growth. That makes Certara the 12,235th largest company in the world by revenue and 2,401st in the United States.
Revenue (ttm)
$408.45M
Revenue Growth
+3.79%
P/S Ratio
3.82
Revenue / Employee
$267,605
Employees
1,576
Market Cap
1.60B
Revenue by Geography
- Americas 291.60M 69.6%
- EMEA 92.63M 22.1%
- Asia Pacific 34.61M 8.3%
Fiscal year ended Dec 31, 2025 See the full Certara breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 418.84M | 33.69M | 8.75% |
| Dec 31, 2024 | 385.15M | 30.81M | 8.70% |
| Dec 31, 2023 | 354.34M | 18.69M | 5.57% |
| Dec 31, 2022 | 335.64M | 49.54M | 17.32% |
| Dec 31, 2021 | 286.10M | 42.57M | 17.48% |
| Dec 31, 2020 | 243.53M | 35.02M | 16.79% |
| Dec 31, 2019 | 208.51M | 44.79M | 27.36% |
| Dec 31, 2018 | 163.72M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Teladoc Health | 2.49B |
| Privia Health Group | 2.36B |
| Evolent Health | 2.10B |
| Omnicell | 1.25B |
| GoodRx Holdings | 785.23M |
| Phreesia | 507.79M |
| HealthStream | 321.12M |
| Omada Health | 309.76M |
CERT News
- 4 hours ago - Certara to Report Third Quarter 2026 Financial Results on November 5th, 2026 - GlobeNewsWire
- 10 days ago - Certara price target raised to $12 from $9 at KeyBanc - TheFly
- 13 days ago - Certara price target raised to $11 from $9 at TD Cowen - TheFly
- 19 days ago - Certara price target raised to $9 from $7.50 at Barclays - TheFly
- 26 days ago - Certara resumed with a Neutral at UBS - TheFly
- 2 months ago - Certara price target raised to $7 from $6 at Baird - TheFly
- 2 months ago - Certara price target lowered to $9 from $10 at Morgan Stanley - TheFly
- 2 months ago - Certara price target raised to $7.50 from $6.50 at Barclays - TheFly